Welcome to our dedicated page for MARA Holdings SEC filings (Ticker: MARA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking how Marathon Digital turns exahash capacity into bitcoin revenue is tough. The company鈥檚 disclosures juggle digital asset impairments, custodial wallet risks, and rapidly expanding mining rigs鈥攖he sort of details that every crypto investor wants but few have time to decode. If you have ever typed 鈥淢arathon Digital SEC filings explained simply鈥� into a search bar, you know the challenge. Stock Titan solves it by turning dense disclosures into clear, actionable insights within seconds.
Our AI reads each Marathon Digital quarterly earnings report 10-Q filing and Marathon Digital annual report 10-K simplified, highlighting hash rate growth, energy contract costs, and bitcoin holdings without the accounting jargon. Need immediate visibility into Marathon Digital insider trading Form 4 transactions or the Marathon Digital Form 4 insider transactions real-time feed? We surface them the moment they hit EDGAR. The same goes for every 8-K鈥擬arathon Digital 8-K material events explained point-by-point鈥攁nd for the Marathon Digital proxy statement executive compensation data that reveals how leadership is paid when bitcoin prices swing.
Whether you鈥檙e monitoring Marathon Digital executive stock transactions Form 4 before earnings, comparing production metrics through our Marathon Digital earnings report filing analysis, or simply understanding Marathon Digital SEC documents with AI, Stock Titan keeps you ahead.
- AI-powered summaries that isolate crypto revenue drivers
- AG真人官方-time alerts on every filing type, from 10-K to 8-K
- Searchable archives covering all historical disclosures
Spend less time parsing PDFs and more time acting on the information that shapes cryptocurrency valuations.
Aclaris Therapeutics (Nasdaq: ACRS) has filed a Form 8-K to inform investors that it will host a conference call on 29 Jul 2025 to review top-line data from its Phase 2a study of ATI-2138, an oral covalent ITK/JAK3 inhibitor for moderate-to-severe atopic dermatitis. Two items are furnished: Exhibit 99.1 (investor presentation) and Exhibit 99.2 (press release). Under Reg FD, Items 7.01 and 8.01 are furnished鈥攏ot filed鈥攕o the information is not subject to Exchange Act liability nor automatically incorporated into other SEC reports.
The 8-K contains no numerical efficacy, safety, or financial metrics. Investors must consult the accompanying exhibits or join the conference call for detailed results. No changes to financial statements or previously issued guidance are included.
Middlesex Water Company (NASDAQ: MSEX) filed a Rule 424(b)(5) prospectus supplement dated 29 Jul 2025 to continue its direct share purchase, sale and dividend reinvestment program (the 鈥淚nvestment Plan鈥�). The filing registers the remaining 712,353 unsold shares of common stock previously registered on Form S-3 (File No. 333-266482) and shifts them to the new shelf registration (File No. 333-287177) dated 12 May 2025. Shares may be issued directly by the company or purchased in the open market; any proceeds provide a flexible, low-cost source of equity capital.
The Plan allows first-time investors to start with $500鈥�$10,000 (or $25 monthly ACH) and existing holders to reinvest dividends or make optional cash purchases up to $25,000 per quarter. Plan shares may occasionally be offered at a discount at the company鈥檚 discretion, though no specific discount is currently set. Key risks highlighted include share-price volatility between order and execution, potential tax liabilities on reinvested dividends, and the possibility that dividends may be reduced or suspended. The company鈥檚 last reported market price was $51.52 on 28 Jul 2025; no proceeds estimate, use-of-funds detail or earnings data are provided in this supplement.
ProPhase Labs (PRPH) disclosed a 22-Jul-25 private placement for $3.0 million cash of 20% OID senior secured convertible notes plus 5.25 million five-year warrants. The two notes carry a $3.75 million face value, 10% interest, mature 22-Jul-26, are pre-payable without penalty, and become convertible only after four months at the lower of 80% of the 10-day VWAP or a fixed cap, subject to a floor and size limits designed to avoid a 鈥渄eath-spiral.鈥�
Net proceeds were $2.75 million. Warrants are exercisable at $0.50. A first-priority lien on substantially all assets secures the notes; the CEO鈥檚 prior $1 million lien is subordinated. Potential dilution is limited to 19.99 % of current shares until stockholder approval; the transfer agent will raise the reserve to 226.3 million shares once additional authorisation is obtained, otherwise the Company must settle in cash.
The board approved the deal. A special meeting is set for 29-Aug-25 (record date 1-Aug-25) to authorise additional shares. Proceeds will fund working capital, general corporate purposes and debt repayment.
Amended Form 6-K corrects a clerical error in the previously filed July 1, 2025 report and restates AGM Group鈥檚 current capital structure.
On 25 Jun 2025 the board:
- Cancelled 12,000 Class B shares held by former CTO Yufeng Mi and 30,000 held by Wenjie Tang.
- Issued 1,200,000 new Class B shares to CEO/CSO Bo Zhu for past and future services; no cash was paid.
After these actions the company has 3,174,163 shares outstanding (1,974,163 Class A; 1,200,000 Class B). Class A carries one vote, Class B five votes. Bo Zhu now owns 37.81 % of equity but controls 75.24 % of total voting power.
The dual-class structure makes AGMH a 鈥渃ontrolled company鈥� under Nasdaq rules, allowing optional exemptions from certain corporate-governance requirements. No financial results, earnings data or operational updates are included.
Mantle Ridge LP, MR Cobalt Advisor LLC and Paul C. Hilal filed Amendment No. 5 to their Schedule 13D on Dollar Tree (DLTR) dated 15 July 2025. The group continues to hold 13,640,904 common shares (6.5% beneficial ownership) and maintains total economic exposure to 23,296,508 shares (11.2% of shares outstanding) through cash- and physically-settled forward structures.
On 11 July 2025 the 鈥淧articipating MR Funds鈥� exercised expiring option agreements with an aggregate strike payment of $889.6 million. Rather than taking delivery, the parties converted the options into new cash-settled and physically-settled forward contracts that mirror the previous exposure, leaving voting and dispositive power unchanged.
The exercise was funded via a $918.1 million secured loan facility from an unaffiliated institution. The loan is collateralised by 10,982,616 pledged shares plus derivatives referencing 10,268,954 shares, but notably contains no margin-call or price-trigger provisions. Voting rights on pledged shares remain with Mantle Ridge unless a foreclosure event occurs.
No additional share purchases or sales were reported; the amendment primarily updates the capital-markets mechanics (option conversion, loan facility) and confirms current ownership percentages. Exhibits include the joint filing agreement, trading data and templates for the derivative contracts.
Amended insider filing: AeroVironment (AVAV) submitted a Form 4/A for Trace E. Stevenson, President 鈥� Autonomous Systems, correcting a clerical error made in the original 27 June 2025 filing. The officer actually received 1,174 restricted stock awards (RSAs) on that date at $0 cost, not the larger amount previously reported. The RSAs vest in three equal installments on 11 July 2026, 2027 and 2028. After the correction, Stevenson鈥檚 direct beneficial ownership is 7,133 common shares rather than 8,140. No open-market purchases or sales occurred; the filing merely aligns reported holdings with the true grant size. The change is modest relative to AeroVironment鈥檚 total shares outstanding and has no direct earnings impact, but it restores disclosure accuracy and compliance with Section 16 requirements.